• Users Online: 72953
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
AdityaS Kelkar,Jai Kelkar,Mounika Bolisetty,ShreekantB Kelkar
Indian Journal of Ophthalmology.2021;69(6)1469
[DOI]
2Biosimilars for the Treatment of Retinal Diseases
Raja Narayanan,Seenu M. Hariprasad,Jay Sheth
Ophthalmic Surgery, Lasers and Imaging Retina.2021;52(5)242
[DOI]
3Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data
Ashish Sharma,M. Hafeez Faridi,Nilesh Kumar,Nikulaa Parachuri,Rohini Sharma,Baruch D. Kuppermann,Francesco Bandello,Anat Loewenstein,Carl D. Regillo
Eye.2020;34(6)1008
[DOI]
4Retina: a unique subspecialty in the biosimilar landscape
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Carl D. Regillo,Francesco Bandello,Baruch D. Kuppermann
Eye.2022;36(6)1145
[DOI]
5Retina: a unique subspecialty in the biosimilar landscape
Weiye Li,Jingfa Zhang
Eye.2024;36(6)215
[DOI]
6Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection
Rohan Merani,Mark W. Johnson,Colin A. McCannel,Harry W. Flynn,Ingrid U. Scott,Alex P. Hunyor
Journal of VitreoRetinal Diseases.2022;6(6)443
[DOI]
7The Future of Biosimilars and Biobetters in Ophthalmology
Ashish Sharma,Baruch D Kuppermann,Anat Loewenstein
US Ophthalmic Review.2022;16(1)6
[DOI]
8Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
Ashish Sharma,Frank G Holz,Carl D Regillo,K Bailey Freund,David Sarraf,Arshad M. Khanani,Caroline Baumal,Nancy Holekamp,Ramin Tadayoni,Nilesh Kumar,Nikulaa Parachuri,Baruch D Kuppermann,Francesco Bandello,Giuseppe Querques,Anat Loewenstein,Sengül Özdek,Kourous Rezai,Kodjikian Laurent,Alper Bilgic,Paolo Lanzetta,Dinah Zur,Nicolas Yannuzzi,Giulia Corradetti,Peter Kaiser,Assaf Hilely,David Boyer,Aleksandra Rachitskaya,Usha Chakravarthy,Maximilian Wintergerst,Valentina Sarao,Barbara Parolini,Prithvi Mruthyunjaya,Quan Dong Nguyen,Diana DO,Pearse A Keane,Tarek Hassan,Jayanth Sridhar,David Eichenbaum,Dilraj Grewal,Martin Splitzer
Expert Opinion on Biological Therapy.2023;23(8)851
[DOI]
9Safety and efficacy of ranibizumab biosimilar (Razumab®) as a cost-effective alternative to the innovator molecule for macular disorders in real-world
Sonal Paliwal,Riddhima Deshpande,Prerna Upadhyay
Indian Journal of Clinical and Experimental Ophthalmology.2023;9(3)329
[DOI]
10Ophthalmic biosimilars and biologics—role of endotoxins
Ashish Sharma,Nilesh Kumar,Baruch D. Kuppermann,Francesco Bandello,Anat Loewenstein
Eye.2020;34(4)614
[DOI]
11Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
Debdulal Chakraborty,Michael W. Stewart,Jay U. Sheth,Tushar K. Sinha,Subhendu Boral,Arnab Das,Soumen Mondal,Angshuman Mukherjee
Ophthalmology and Therapy.2021;10(2)337
[DOI]
12Biosimilars for Retinal Diseases: An Update
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Francesco Bandello,Baruch D. Kuppermann,Anat Loewenstein
American Journal of Ophthalmology.2021;224(2)36
[DOI]
13Biosimilars for Retinal Diseases: A Review of the Literature
Rachel N. Israilevich,Kannan Sharma,Matthew R. Starr
International Ophthalmology Clinics.2024;64(1)129
[DOI]
14Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
Lalit Verma,Mithun Thulasidas,Ajay Purohit,Avnindra Gupta,Ritesh Narula,Dinesh Talwar
Indian Journal of Ophthalmology.2021;69(2)347
[DOI]
15A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration
Ramandeep Singh,Rohan Chauhan,Ashish Saxena,Anup Shah,Laxshmi Mondal,Dhananjay Bakhle,Chirag Shah,Arpit Shah,Shashank Deoghare,Neelakant Krishnan,Neelima Godse
Indian Journal of Ophthalmology.2022;70(8)3008
[DOI]
16Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Anat Loewenstein,Francesco Bandello,Baruch D Kuppermann
Expert Opinion on Biological Therapy.2023;23(8)689
[DOI]
17Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Jingfa Zhang,Jingxiang Zhang,Chaoyang Zhang,Jingting Zhang,Limin Gu,Dawei Luo,Qinghua Qiu
Cells.2022;11(21)3362
[DOI]
18Immunogenicity: Clouding the Future of Intravitreal Therapy
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Francesco Bandello,Baruch D. Kuppermann
Ocular Immunology and Inflammation.2023;31(9)1746
[DOI]
19Biosimilars in the Treatment of Retinal Disease in the United States
Priya S. Vakharia,David A. Eichenbaum,Caroline R. Baumal
Ophthalmic Surgery, Lasers and Imaging Retina.2023;54(6)362
[DOI]
20Biosimilars in Ophthalmology: Financial Implications and Beyond
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Anat Loewenstein,Francesco Bandello,Baruch D Kuppermann
US Ophthalmic Review.2022;16(2)98
[DOI]
21Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
JayU Sheth,MichaelW Stewart,Manoj Khatri,ShashankR Gupta,Shobhit Chawla,Anand Rajendran,Raja Narayanan
Indian Journal of Ophthalmology.2021;69(2)352
[DOI]
22Erratum: Ophthalmic biosimilars: Lessons from India
JayU Sheth,MichaelW Stewart,Manoj Khatri,ShashankR Gupta,Shobhit Chawla,Anand Rajendran,Raja Narayanan
Indian Journal of Ophthalmology.2020;68(10)2331
[DOI]
23Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect
Ashish Sharma,Nilesh Kumar,Francesco Bandello,Anat Loewenstein,Baruch D. Kuppermann
Eye.2020;34(6)1006
[DOI]
24Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
Ashish Sharma,Nilesh Kumar,Nikulaa Parachuri,Francesco Bandello,Baruch D. Kuppermann,Anat Loewenstein
Eye.2022;36(5)1106
[DOI]
25Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Abraham Hang,Samuel Feldman,Aana P. Amin,Jorge A. Rivas Ochoa,Susanna S. Park
Pharmaceuticals.2023;16(8)1140
[DOI]

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal